Bluebird bio : Management Change/Compensation Form 8 K
June 24, 2024 at 01:05 pm
Share
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 20, 2024, the board of directors (the "Board") of bluebird bio, Inc. (the "Company") appointed Michael Cloonan to the Board as a Class I director, effective June 20, 2024.
Mr. Cloonan is eligible for compensation as set forth in the Company's Non-EmployeeDirector Compensation Policy, including receipt of an annual retainer of $45,000 for his Board service and an initial award of (i) a stock option to purchase 74,775 shares of the Company's common stock and (ii) 37,350 restricted stock units. The stock options and restricted stock units will vest ratably over three years in annual installments.
Mr. Cloonan will also enter into the Company's standard indemnification agreement for directors and officers. Mr. Cloonan does not have any family relationship with any other director or executive officer of the Company, is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K,and there are no arrangements or understandings between Mr. Cloonan and any other persons pursuant to which he was selected as a director.
Attachments
Original Link
Permalink
Disclaimer
Bluebird Bio Inc. published this content on
24 June 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
24 June 2024 12:04:41 UTC.
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).
BLUEBIRD BIO, INC. 
